Find and Pitch Jounalists, Get Your Story Covered

Tags: Glox Therapeutics\bacteriocin development programme\antimicrobial resistance\AMR\Boehringer Ingelheim Venture Fund \

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 5 months ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - 5 months ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - 5 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 5 months ago STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data - 6 months ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - 7 months ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - 7 months ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - 7 months ago
2	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: In another blow, Argenx antibody therapy fails in trial for skin blistering condition - 5 months ago
3	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - 5 months ago
4	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - 5 months ago STAT+: Startup launches with $245 million for twice yearly asthma treatment - 7 months ago
5	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 5 months ago
6	Nick Paul Taylor MedTech Dive Top 5 Mario Kart Player. Gaming	Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma - 5 months ago
7	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	A plot to solve the ‘whack-a-mole’ of drug discovery - 5 months ago Why Cerevel Therapeutics has risen 50% in three days without changing anything - 5 months ago Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis - 6 months ago
8	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing	Oncology drugmakers seek the sweet spot between efficacy and tolerability - 5 months ago An ‘inverse vaccine’ takes aim at autoimmune diseases - 7 months ago
9	Brittany Trang STAT News Health care business reporter. PhD. Indie rock fan. health carebusiness reporting	STAT+: Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy - 5 months ago
10	Ben Fidler Pharma Voice	CRISPR eyes autoimmune disease in revamp of cell therapy plans - 5 months ago

Journalists covering Glox Therapeutics\